ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR
Open Access
- 1 June 2025
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 205, 108594
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancerAnnals of Oncology, 2022
- Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancerJournal of Cancer Research and Clinical Oncology, 2022
- Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189Annals of Oncology, 2021
- Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosisCellular Oncology, 2021
- ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical applicationCancer Letters, 2020
- Functional loss of ARID1A is tightly associated with high PD‐L1 expression in gastric cancerInternational Journal of Cancer, 2019
- ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosisTumor Biology, 2014
- The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cellsTumor Biology, 2013
- Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysisTumor Biology, 2012